TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9222631

Group type: EXPERIMENTAL
Intervention: Great auricular nerve preserved
Number of subjects: 31

Group type: COMPARATOR
Intervention: Great auricular nerve sacrificed
Number of subjects: 31
Study: 7690383

Group type: EXPERIMENTAL
Intervention: Midodrine 10 mg three times daily
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Midodrine 5 mg three times daily
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Midodrine 2.5 mg three times daily
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study: 3319543

Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 622

Group type: EXPERIMENTAL
Intervention: Phenobarbital
Number of subjects: 622

Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 622

Group type: EXPERIMENTAL
Intervention: Primidone
Number of subjects: 622

Group type: EXPERIMENTAL
Intervention: All four drugs combined
Number of subjects: 622

Group type: EXPERIMENTAL
Intervention: Carbamazepine and Phenytoin
Number of subjects: 622

Group type: COMPARATOR
Intervention: Behavioral toxicity battery
Number of subjects: 622
Study: 29169968

Group type: EXPERIMENTAL
Intervention: HP35% hydrogen peroxide
Number of subjects: 25

Group type: COMPARATOR
Intervention: HP15% hydrogen peroxide
Number of subjects: 25
Study: 28208819

Group type: EXPERIMENTAL
Intervention: Paper version of the Canadian Diet History Questionnaire II (CDHQ‐II)
Number of subjects: 648

Group type: EXPERIMENTAL
Intervention: Web version of the Canadian Diet History Questionnaire II (CDHQ‐II)
Number of subjects: 648

Group type: COMPARATOR
Intervention: Web version of the CDHQ‐II
Number of subjects: 648

Group type: COMPARATOR
Intervention: Paper version of the CDHQ‐II
Number of subjects: 648
Study: 24131370

Group type: EXPERIMENTAL
Intervention: Neater Uni‐wheelchair
Number of subjects: 4

Group type: COMPARATOR
Intervention: Standard dual handrim Action 3 wheelchair
Number of subjects: 4
Study: 23453448

Group type: EXPERIMENTAL
Intervention: Active CPAP
Number of subjects: 46

Group type: COMPARATOR
Intervention: Sham CPAP
Number of subjects: 46
Study: 20842172

Group type: EXPERIMENTAL
Intervention: Condition 1: self-selection of snacks
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Condition 2: preload (300 kcal: 40% protein, 40% carbohydrates, 20% fat) at 15 min before meals
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Condition 3: preload (300 kcal: 40% protein, 40% carbohydrates, 20% fat) at ∼ 50 min before meals
Number of subjects: 10
Study: 18347974

Group type: EXPERIMENTAL
Intervention: Right Nostril Yoga Breathing (RNYB)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Alternate Nostril Yoga Breathing (ANYB)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Left Nostril Yoga Breathing (LNYB)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Breath Awareness (BAW)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Normal Breathing (CTL)
Number of subjects: 21
Study: 16418802

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART) with observed viral load blips
Number of subjects: 16

Group type: COMPARATOR
Intervention: Antiretroviral therapy (ART) without observed viral load blips
Number of subjects: 16
Study: 12918866

Group type: EXPERIMENTAL
Intervention: Static stretching for 30 seconds (n = 26)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Static stretching for 1 minute (n = 24)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Static stretching for 2 minutes (n = 27)
Number of subjects: 101

Group type: COMPARATOR
Intervention: No stretch control group (n = 24)
Number of subjects: 101
Study: 10856094

Group type: EXPERIMENTAL
Intervention: Docetaxel 100 mg/m² (D100)
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Docetaxel 75 mg/m² (D75)
Number of subjects: 373

Group type: COMPARATOR
Intervention: Vinorelbine or Ifosfamide (V/I)
Number of subjects: 373
Study: 9052337

Group type: EXPERIMENTAL
Intervention: t‐PA (0.8 mg/kg, up to a maximum dose of 80 mg)
Number of subjects: 1425

Group type: EXPERIMENTAL
Intervention: Invasive strategy (coronary arteriography with percutaneous angioplasty, if feasible)
Number of subjects: 1425

Group type: EXPERIMENTAL
Intervention: Patients > 75 years of age
Number of subjects: 1425

Group type: EXPERIMENTAL
Intervention: Higher heparin levels
Number of subjects: 1425

Group type: EXPERIMENTAL
Intervention: Higher peak D‐dimer levels
Number of subjects: 1425

Group type: EXPERIMENTAL
Intervention: Lower nadir fibrinogen levels
Number of subjects: 1425

Group type: COMPARATOR
Intervention: t‐PA
Number of subjects: 1425
Study: 8466349

Group type: EXPERIMENTAL
Intervention: Heparin-coated circuit (Duraflo II)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (noncoated circuit)
Number of subjects: 30
Study: 30040767

Group type: EXPERIMENTAL
Intervention: anodal M1-tDCS
Number of subjects: 32

Group type: COMPARATOR
Intervention: sham stimulation
Number of subjects: 32
Study: 28557558

Group type: EXPERIMENTAL
Intervention: Grow2Gether intervention (Facebook peer-group)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Text message appointment reminders (Control)
Number of subjects: 87
Study: 26051095

Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid (ALA) 600 mg for 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23288496

Group type: EXPERIMENTAL
Intervention: Universal school-based depression prevention programme
Number of subjects: 834

Group type: COMPARATOR
Intervention: Control programmes
Number of subjects: 834
Study: 20601692

Group type: EXPERIMENTAL
Intervention: Infant HIV infection
Number of subjects: 848

Group type: EXPERIMENTAL
Intervention: Maternal plasma viral load >100,000 copies ml⁻¹
Number of subjects: 848

Group type: EXPERIMENTAL
Intervention: Maternal age < 20 years
Number of subjects: 848
Study: 18190710

Group type: EXPERIMENTAL
Intervention: Probiotic containing 4 strains of live bacteria taken daily for 3 months
Number of subjects: 147

Group type: COMPARATOR
Intervention: Identical placebo taken daily for 3 months
Number of subjects: 147
Study: 17174182

Group type: EXPERIMENTAL
Intervention: Intensive medical therapy
Number of subjects: 205

Group type: COMPARATOR
Intervention: Coronary revascularization
Number of subjects: 205
Study: 12711121

Group type: EXPERIMENTAL
Intervention: Gemcitabine (GEM) 1000 mg/m(2), days 1, 8 and 15, every 4 weeks
Number of subjects: 169

Group type: COMPARATOR
Intervention: Cisplatin (100 mg/m(2), day 1) plus Vindesine (3 mg/m(2), days 1 and 15) (PV)
Number of subjects: 169
Study: 10921160

Group type: EXPERIMENTAL
Intervention: Zhu Yu Hua Tan Tang plus general treatment
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Zhu Yu Hua Tan Tang
Number of subjects: 44

Group type: COMPARATOR
Intervention: Mannitol
Number of subjects: 44
Study: 8832309

Group type: EXPERIMENTAL
Intervention: Celiprolol
Number of subjects: 132

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 132
Study: 1570392

Group type: EXPERIMENTAL
Intervention: pindolol (80 mg over 3 days)
Number of subjects: 10

Group type: COMPARATOR
Intervention: buspirone (30 mg orally)
Number of subjects: 10
Study: 3891779

Group type: EXPERIMENTAL
Intervention: Directigen tested within 4 hours of sampling
Number of subjects: 964

Group type: COMPARATOR
Intervention: Directigen tested after overnight storage
Number of subjects: 964
Study: 30044439

Group type: EXPERIMENTAL
Intervention: Anthocyanines (60 mg/day)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Xanthophylls (6 mg L + 2 mg Z/day)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Anthocyanines (60 mg/day) + Xanthophylls (6 mg L + 2 mg Z/day)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control (no supplementation)
Number of subjects: 72
Study: 27454919

Group type: EXPERIMENTAL
Intervention: Corticosteroid-free regimen with Tac and MMF starting at 3 g/d, dose adjusted from day 5
Number of subjects: 187

Group type: COMPARATOR
Intervention: Corticosteroid regimen with Tac and fixed-dose MMF (2 g/d)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Corticosteroid-free regimen with Tac and MMF
Number of subjects: 187
Study: 24903207

Group type: EXPERIMENTAL
Intervention: Recreational football (F; n = 9)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Resistance training (R; n = 9)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Inactive controls (C; n = 8)
Number of subjects: 26
Study: 22420890

Group type: EXPERIMENTAL
Intervention: Baseline plasma FABP4 levels
Number of subjects: 578

Group type: EXPERIMENTAL
Intervention: Highest tertile of FABP4 in women
Number of subjects: 578
Study: 20357372

Group type: EXPERIMENTAL
Intervention: GLAR + MET + EXE
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: GLAR + MET + SITA
Number of subjects: 48

Group type: COMPARATOR
Intervention: GLAR + MET
Number of subjects: 48
Study: 16956036

Group type: EXPERIMENTAL
Intervention: ST analysis of fetal ECG (group A)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Standard monitoring methods (group B)
Number of subjects: 134
Study: 14871281

Group type: EXPERIMENTAL
Intervention: Capsaicin-containing red pepper sauce
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 10
Study: 11752915

Group type: EXPERIMENTAL
Intervention: Atropine (0.01 mg/kg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Isoproterenol (0.5‐1.0 microg/kg/min)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Isoproterenol
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 80
Study: 9246136

Group type: EXPERIMENTAL
Intervention: Prednisolone (1 mg/kg/day orally for seven days)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 54
Study: 8502357

Group type: EXPERIMENTAL
Intervention: Sygen‐‐monosialoganglioside 40 mg daily
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo (Vitamin PP)
Number of subjects: 65
Study: 3329968

Group type: EXPERIMENTAL
Intervention: Diflunisal (500 mg orally, twice daily)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Piroxicam (20 mg orally, once daily)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Diflunisal
Number of subjects: 44

Group type: COMPARATOR
Intervention: Piroxicam
Number of subjects: 44
Study: 31278194

Group type: EXPERIMENTAL
Intervention: Ferric citrate coordination complex (two tablets per meal, 210 mg ferric iron per tablet)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 203
Study: 28039097

Group type: EXPERIMENTAL
Intervention: 3D laparoscopic vision
Number of subjects: 20

Group type: COMPARATOR
Intervention: 2D laparoscopic vision
Number of subjects: 20
Study: 24978872

Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg/day (up to 100 mg/day)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 24239019

Group type: EXPERIMENTAL
Intervention: Buttonhole needling
Number of subjects: 140

Group type: COMPARATOR
Intervention: Standard needling
Number of subjects: 140
Study: 22244561

Group type: EXPERIMENTAL
Intervention: Concomitant tricuspid annuloplasty (Cosgrove‐Edwards annuloplasty ring)
Number of subjects: 44

Group type: COMPARATOR
Intervention: No concomitant tricuspid annuloplasty (Control)
Number of subjects: 44
Study: 20033601

Group type: EXPERIMENTAL
Intervention: Image-guided neurosurgery
Number of subjects: 12
Study: 17515857

Group type: EXPERIMENTAL
Intervention: Antithrombin III (AT) agent at 1,500 U/24 h (combined group) for 3 days
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Antithrombin III (AT) agent at 500 U/8 h (divided group) for 3 days
Number of subjects: 24
Study: 16264051

Group type: EXPERIMENTAL
Intervention: Aspergillus fumigatus inhalation
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo inhalation
Number of subjects: 28
Study: 11850098

Group type: EXPERIMENTAL
Intervention: Acarbose, 100 mg thrice daily
Number of subjects: 27

Group type: COMPARATOR
Intervention: Glibenclamide, 1 mg thrice daily
Number of subjects: 27
Study: 10201424

Group type: EXPERIMENTAL
Intervention: Visual simple reaction time (SRT) task
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Uncued four choice reaction time (CRT) task
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Fully cued four choice reaction time (CRT) task
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: S1-S2 interval effects on CRTs
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 200 ms S1-S2 interval
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 1600 ms S1-S2 interval
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 800 ms and 3200 ms S1-S2 intervals
Number of subjects: 23
Study: 7572739

Group type: EXPERIMENTAL
Intervention: Preterm formula (pre)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Preterm formula with ribonucleotides (pre+RN)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Breast-fed babies (reference group)
Number of subjects: 68
Study: 2157581

Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 109592

Group type: EXPERIMENTAL
Intervention: 10 or 50 microgram doses of meningococcal group A polysaccharide vaccine
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: 50 microgram dose of meningococcal group A polysaccharide vaccine
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: 10 microgram dose of meningococcal group A polysaccharide vaccine
Number of subjects: 108
Study: 31491340

Group type: EXPERIMENTAL
Intervention: SSR markers identified from transcriptome assembly
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: cDNA library sequencing using Illumina NovaSeq. 6000
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Geographical clustering of accessions
Number of subjects: 88
Study: 27343344

Group type: EXPERIMENTAL
Intervention: TENS treatment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 30
Study: 25518053

Group type: EXPERIMENTAL
Intervention: Azathioprine (AZA)
Number of subjects: 255
Study: 23897241

Group type: EXPERIMENTAL
Intervention: Endotracheal tube cleaning three times a day (group A)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Endotracheal tube cleaning twice daily (group B)
Number of subjects: 45

Group type: COMPARATOR
Intervention: No endotracheal tube cleaning (group C)
Number of subjects: 45
Study: 21827704

Group type: EXPERIMENTAL
Intervention: Latex sublingual immunotherapy
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 19841762

Group type: EXPERIMENTAL
Intervention: Er:YAG laser ablation on dentin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (ground using #600 SiC paper)
Number of subjects: 20
Study: 16759925

Group type: EXPERIMENTAL
Intervention: ICSI zygotes
Number of subjects: 250

Group type: COMPARATOR
Intervention: IVF zygotes
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: ICSI zygotes from severe oligozoospermia
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: ICSI zygotes from azoospermia
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: ICSI zygotes from oligozoospermia
Number of subjects: 250
Study: 15563438

Group type: EXPERIMENTAL
Intervention: High calcium dairy drink
Number of subjects: 154

Group type: COMPARATOR
Intervention: Control drink reconstituted with water
Number of subjects: 154
Study: 12516677

Group type: EXPERIMENTAL
Intervention: Sonicare Elite toothbrush
Number of subjects: 45

Group type: COMPARATOR
Intervention: Sonicare Advance toothbrush
Number of subjects: 45
Study: 9582586

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (100 mg)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Ofloxacin (200 mg)
Number of subjects: 7
Study: 8291826

Group type: EXPERIMENTAL
Intervention: Annual screening with mammography and physical examination
Number of subjects: 2

Group type: COMPARATOR
Intervention: Annual screening with mammography
Number of subjects: 2
Study: 2491404

Group type: EXPERIMENTAL
Intervention: tiaprofenic acid
Number of subjects: 32

Group type: COMPARATOR
Intervention: indomethacin
Number of subjects: 32
Study: 1000146

Group type: EXPERIMENTAL
Intervention: Continuously reinforced group
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Variably reinforced group
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 8
Study: 31882527

Group type: EXPERIMENTAL
Intervention: Transdermal glyceryl trinitrate (GTN) for 7 days
Number of subjects: 4011

Group type: COMPARATOR
Intervention: No GTN
Number of subjects: 4011
Study: 28181363

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 25906949

Group type: EXPERIMENTAL
Intervention: Boron supplementation (10 mg/day)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 113
Study: 22771782

Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 12
Study: 20335550

Group type: EXPERIMENTAL
Intervention: 1 capsule/day of omega-3 PUFA supplement providing 0.84 g DHA + EPA
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 3 capsules/day of omega-3 PUFA supplement providing 2.52 g DHA + EPA
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 6 capsules/day of omega-3 PUFA supplement providing 5.04 g DHA + EPA
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 9 capsules/day of omega-3 PUFA supplement providing 7.56 g DHA + EPA
Number of subjects: 48
Study: 18313671

Group type: EXPERIMENTAL
Intervention: Electrosurgical incision
Number of subjects: 50

Group type: COMPARATOR
Intervention: Bougie dilation
Number of subjects: 50
Study: 16131771

Group type: EXPERIMENTAL
Intervention: Intramuscular midazolam
Number of subjects: 115

Group type: COMPARATOR
Intervention: Intravenous diazepam (without prior i.v. access)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Intravenous diazepam (with prior i.v. access)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Intravenous diazepam
Number of subjects: 115
Study: 12149842

Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery
Number of subjects: 113
Study: 10503678

Group type: EXPERIMENTAL
Intervention: Iron treatment for pupils with s-ferritin <15 microg/l, duration of 3 months
Number of subjects: 176

Group type: COMPARATOR
Intervention: Screening for anaemia and iron deficiency
Number of subjects: 176
Study: 8607723

Group type: EXPERIMENTAL
Intervention: Active drug treatment (chlorthalidone 15 mg/d, acebutolol hydrochloride 400 mg/d, doxazosin mesylate 2 mg/d, amlodipine besylate 5 mg/d, enalapril maleate 5 mg/d)
Number of subjects: 902

Group type: EXPERIMENTAL
Intervention: Active drug treatment (all active drugs combined)
Number of subjects: 902

Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 902

Group type: EXPERIMENTAL
Intervention: Active drug treatment
Number of subjects: 902

Group type: COMPARATOR
Intervention: Lifestyle intervention only
Number of subjects: 902
Study: 1953524

Group type: EXPERIMENTAL
Intervention: Interferon alpha 2b (3 million units subcutaneously thrice weekly for 24 weeks)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Interferon alpha 2b
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (observed without treatment for 12 months)
Number of subjects: 40
Study: 7050035

Group type: EXPERIMENTAL
Intervention: misonidazole (2.0 gm per m2 body surface) with radiation
Number of subjects: 97

Group type: COMPARATOR
Intervention: radiation (3600 rad in 17 days) without misonidazole
Number of subjects: 97
Study: 31430524

Group type: EXPERIMENTAL
Intervention: Accommodating child's healthy preferences
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Accommodating child's indulgent preferences
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imposing own preferences
Number of subjects: 0
Study: 28398968

Group type: EXPERIMENTAL
Intervention: AtDCS+treadmill
Number of subjects: 18

Group type: COMPARATOR
Intervention: treadmill
Number of subjects: 18

Group type: COMPARATOR
Intervention: StDCS+treadmill
Number of subjects: 18
Study: 25736045

Group type: EXPERIMENTAL
Intervention: Ferric Citrate (FC)
Number of subjects: 441
Study: 25163906

Group type: EXPERIMENTAL
Intervention: Cilengitide 2000 mg intravenously twice weekly combined with temozolomide chemoradiotherapy
Number of subjects: 545

Group type: COMPARATOR
Intervention: Temozolomide chemoradiotherapy alone
Number of subjects: 545

Group type: EXPERIMENTAL
Intervention: Cilengitide
Number of subjects: 545
Study: 22890251

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention involving evidence-based practices and the Comprehensive Unit-based Safety Program
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study: 19648823

Group type: EXPERIMENTAL
Intervention: Raltegravir (400 mg twice a day after 48 weeks)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Efavirenz (600 mg every day)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Raltegravir
Number of subjects: 198

Group type: COMPARATOR
Intervention: Efavirenz
Number of subjects: 198
Study: 17452676

Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 4445

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4445
Study: 16987587

Group type: EXPERIMENTAL
Intervention: Group 3 (specific training method not detailed)
Number of subjects: 61

Group type: COMPARATOR
Intervention: All groups (including Group 1 and Group 2)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Whole body manikins
Number of subjects: 61
Study: 14626331

Group type: EXPERIMENTAL
Intervention: Electronic Data Capture (EDC) version of the Asthma Quality of Life Questionnaire (AQLQ(S))
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Electronic Data Capture (EDC) version of the Pediatric Asthma Quality of Life Questionnaire (PAQLQ(S))
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Electronic Data Capture (EDC) version of the Pediatric Asthma Caregiver's Quality of Life Questionnaire (PACQLQ)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Preference for electronic version
Number of subjects: 154
Study: 10868771

Group type: EXPERIMENTAL
Intervention: Support intervention with visits from a 'similar other' (trained veterans) during hospital stay
Number of subjects: 190

Group type: COMPARATOR
Intervention: Usual hospital care
Number of subjects: 190
Study: 8800392

Group type: EXPERIMENTAL
Intervention: Naltrexone (NTX), 50 mg/day, po
Number of subjects: 16

Group type: COMPARATOR
Intervention: Inactive placebo
Number of subjects: 16
Study: 1731285

Group type: EXPERIMENTAL
Intervention: Transdermal E2 0.1 mg for 24.5 days of each 28‐day cycle for 96 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Transdermal E2 0.1 mg plus 10 mg of medroxyprogesterone acetate from days 13‐25 of each cycle
Number of subjects: 60
Study: 6419578

Group type: EXPERIMENTAL
Intervention: bepridil
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20